Israeli biomed company Evogene, which genetically engineers plant seeds, is in talks to go public on Nasdaq at a company value of $250 million. Calcalist reports that the IPO will be led by Deutsche Bank and Credit Swiss. Evogene is currently being traded in the Tel Aviv stock exchange at a company value of $210 million.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments